Comparative studies of a retrovirus versus a poxvirus vector in whole tumor-cell vaccines

Cancer Research

Volumn 59, Issue 20, 1999, Pages 5106-5111

  Hodge, James W ^a   Schlom, Jeffrey ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR CELL VACCINE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOLOGY; CARCINOMA CELL; CELL SURFACE; CONTROLLED STUDY; FEMALE; FOWLPOX VIRUS; GENE EXPRESSION; LUNG METASTASIS; MOUSE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; RETROVIRUS; TRANSGENE; VACCINIA VIRUS; VIRUS RECOMBINANT;

ANIMALS; ANTIGENS, CD80; CANCER VACCINES; FEMALE; GENETIC VECTORS; IMMUNIZATION; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; RETROVIRIDAE; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 0032697559     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Chen, L., McGowan, P., Ashe, S., Johnston, J., Li, Y., Hellstrom, I., and Hellstrom, K. E. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med., 179: 523-532, 1994.
2. Nemunaitis, J., Bohart, C., Fong, T., Meyer, W., Edelman, G., Paulson, R. S., Orr, D., Jain, V., O'Brien, J., Kuhn, J., Kowal, K. J., Burkeholder, S., Bruce, J., Ognoskie, N., Wynne, D., Martineau, D., and Ando, D. Phase I trial of retroviral vector-mediated interferon (IFN)-γ gene transfer into autologous tumor cells in patients with metastatic melanoma. Cancer Gene Ther., 5: 292-300, 1998.
3. Gunji, Y., Tasaki, K., Tagawa, M., Matsubara, H., Takenaga, K., Suzuki, T., Asano, T., Ochiai, T., Isono, K., and Sakiyama, S. Inhibition of peritoneal dissemination of murine colon carcinoma cells by administrating retrovirus harboring IL-2 gene. Cancer Gene Ther., 5: 339-343, 1998.
4. Tasaki, K., Tagawa, M., Gunji, Y., Matsubara, H., Takenaga, K., Muramatsu, M., Fujimura, S., Suzuki, T., Asano, T., Ochiai, T., Isono, K., Kouzu, T., and Sakiyama, S. Inhibition of experimental lung metastasis of murine colon carcinoma cells depends on the amount of interleukin-2 secreted from the transduced cells. Anticancer Res., 18: 813-817, 1998.
5. Aruga, A., Tanigawa, K., Aruga, E., Yu, H., and Chang, A. E. Enhanced adjuvant effect of granulocyte-macrophage colony-stimulating factor plus interleukin-12 compared with either alone in vaccine-induced tumor immunity. Cancer Gene Ther., 6: 89-95, 1999.
6. Hsieh, C. L., Pang, V. F., Chen, D. S., and Hwang, L. H. Regression of established mouse leukemia by GM-CSF-transduced tumor vaccine: implications for cytotoxic T lymphocyte responses and tumor burdens. Hum. Gene Ther., 8: 1843-1854, 1997.
7. McLaughlin, J. P., Abrams, S., Kantor, J., Dobrzanski, M. J., Greenbaum, J., Schlom, J., and Greiner, J. W. Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM- CSF) induces tumor regression and long-lasting systemic immunity. J. Immunother., 20: 449-459, 1997.
8. Lotze, M. T., Zitvogel, L., Campbell, R., Robbins, P. D., Elder, E., Haluszczak, C., Martin, D., Whiteside, T. L., Storkus, W. J., and Tahara, H. Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials Ann. NY Acad. Sci., 795: 440-454, 1996.
9. Tahara, H., Zitvogel, L., Storkus, W. J., Zeh, H. J., III, McKinney, T. G., Schreiber, R. D., Gubler, U., Robbins, P. D., and Lotze, M. T. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol., 154: 6466-6474, 1995.
10. Marti, W. R., Oertli, D., Meko, J. B., Norton, J. A., and Tsung, K. Induction of antigen-presenting capacity in tumor cells upon infection with non-replicating recombinant vaccinia virus encoding murine MHC class II and costimulatory molecules. J. Immunol. Methods, 200: 191-198, 1997.
11. Cavallo, F., Martin-Fontecha, A., Bellone, M., Heltai, S, Gatti, E., Tornaghi, P., Freschi, M., Forni, G., Dellabona, P., and Casorati, G. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur. J. Immunol., 25: 1154-1162, 1995.
12. Hodge, J. W., Abrams, S., Schlom, J., and Kantor, J. A. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res., 54: 5552-5555, 1994.
13. Uzendoski, K., Kantor, J. A., Abrams, S. I., Schlom, J., and Hodge, J. W. Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: induction and potentiation of antitumor responses. Hum. Gene Ther., 8: 851-850, 1997.
14. Hellstrom, K. E., Gladstone, P., and Hellstrom, I. Cancer vaccines: challenges and potential solutions. Mol. Med. Today, 3: 286-290, 1997.
15. Dunussi-Joannopoulos, K., Weinstein, H. I., Nickerson, P. W., Strom, T. B., Burakoff, S. J., Croop, J. M., and Arceci, R. J. Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood, 87: 2938-2946, 1996.
16. Townsend, S. E., Su, F. W., Atherton, J. M., and Allison, J. P. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res., 54: 6477-6483, 1994.
17. Kawakita, M., Rao, G. S., Ritchey, J. K., Ornstein, D. K., Hudson, M. A., Tartaglia, J., Paoletti, E., Humphrey, P. A., Harmon, T. J., and Ratliff, T. L. Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth [see comments]. J. Natl. Cancer Inst., 89, 428-436, 1997.
18. Fox, B. A., Spiess, P. J., Kasid, A., Puri, R., Mule, J. J., Weber, J. S., and Rosenberg, S. A. In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes. J. Biol. Response Modif., 9: 499-511, 1990.
19. Wexler, H. Accurate identification of experimental pulmonary metastases. J. Natl. Cancer Inst., 36: 641-645, 1966.
20. Hodge, J. W., McLaughlin, J. P., Kantor, J. A., and Schlom, J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine, 15: 759-768, 1997.
21. Human Gene Therapy Protocols. Hum. Gene Ther., 9: 928-976, 1998.
22. Leach, D. R., Krummel, M. F., and Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science (Washington DC), 271, 1734-1736, 1996.
23. Kwon, E. D., Hurwitz, A. A., Foster, B. A., Madias, C., Feldhaus, A. L., Greenberg, N. M., Burg, M. B., and Allison, J. P. Manipulation of T cell costimulalory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl. Acad. Sci. USA, 94: 8099-8103, 1997.
24. Grignani, F., Kinsella, T., Mencarelli, A., Valtieri, M., Riganelli, D., Lanfrancone, L., Peschle, C., Nolan, G. P., and Pelicci, P. G. High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res., 58: 14-19, 1998.
25. Dachs, G. U., Dougherty, G. J., Stratford, I. J., and Chaplin, D. J. Targeting gene therapy to cancer: a review. Oncol. Res., 9: 313-325, 1997.
26. Kim, S. H., Yu, S. S., Park, J. S., Robbins, P. D., An, C. S., and Kim, S. Construction of retroviral vectors with improved safety, gene expression, and versatility. J. Virol., 72: 994-1004, 1998.
27. Naldini, L. Lentiviruses as gene transfer agents for delivery to non-dividing cells. Curr. Opin. Biotechnol., 9: 457-463, 1998.
28. Wallack, M. K., Sivanandham, M., Ditaranto, K., Shaw, P., Balch, C. M., Urist, M. M., Bland, K. I., Murray, D. Robinson, W. A., Flaherty, L., Richards, J. M., Rosen, L., and Banolucci, A. A. Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a Phase III, multi-institutional trial. Ann. Surg., 226: 198-206, 1997.
29. Marshall, J. L., Richmond, E., Pedicano, J., Tsang, A., and Schlom, J. Phase 1/II trial of Vaccinia-CEA and ALVAC-CEA in patients with advanced CEA-bearing tumors. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 18: 1609a, 1999.
30. Moss, B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safely. Proc. Natl. Acad. Sci. USA, 93: 11341-11348, 1996.
31. He, X. S., Rivkina, M., and Robinson, W. S. Construction of adenoviral and retroviral vectors coexpressing the genes encoding the hepatitis B surface antigen and B7-1 protein. Gene (Amst.), 175: 121-125, 1996.
32. Zitvogel, L., Tahara, H., Cai, Q., Storkus, W. J., Muller, G., Wolf, S. F., Gately, M., Robbins, P. D., and Lotze, M. T. Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Hum. Gene Ther., 5: 1493-1506, 1994.
33. Dubey, C., Croft, M., and Swain, S. L. Costimulatory requirements of naive CD4+ T cells. ICAM-1 or B7-1 can costimulate naive CD4 T cell activation but both are required for optimum response. J. Immunol., 155: 45-57, 1995.
34. Ockenhouse, C. F., Sun, P. F., Lanar, D. E., Wellde, B. T., Hall, B. T., Kester, K., Stoute, J. A., Magill, A., Krzych, U., Farley, L., Wirtz, R. A., Sadoff, J. C., Kaslow, D. C., Kumar, S., Church, L. W., Crutcher, J. M., Wizel, B., Hoffman, S., Lalvani, A., Hill, A. V., Tine, J. A., Guito, K. P., de Taisne, C., Anders, R., Horii, T., Paoletti, E., and Ballou, W. R. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J. Infect. Dis., 177: 1664-1673, 1998.